Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

1.340 +0.050 (+3.88%)
Delayed Quote Updated: 2:12 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,903
Open 1.290
Bid (Size) 1.310 (26,700)
Ask (Size) 1.390 (2,100)
Prev. Close 1.290
Today's Range 1.265 - 1.345
52wk Range 1.265 - 3.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain 
From OKYO Pharma LTD
Via GlobeNewswire

Performance

YTD
-39.9%
-39.9%
1 Month
-11.3%
-11.3%
3 Month
-14.6%
-14.6%
6 Month
-20.2%
-20.2%
1 Year
-33.3%
-33.3%

More News

Read More
News headline image
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Director
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chairman
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chairman
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
From OKYO Pharma LTD
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill

Frequently Asked Questions

Is OKYO Pharma Limited - Ordinary Shares publicly traded?
Yes, OKYO Pharma Limited - Ordinary Shares is publicly traded.
What exchange does OKYO Pharma Limited - Ordinary Shares trade on?
OKYO Pharma Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for OKYO Pharma Limited - Ordinary Shares?
The ticker symbol for OKYO Pharma Limited - Ordinary Shares is OKYO on the Nasdaq Stock Market
What is the current price of OKYO Pharma Limited - Ordinary Shares?
The current price of OKYO Pharma Limited - Ordinary Shares is 1.340
When was OKYO Pharma Limited - Ordinary Shares last traded?
The last trade of OKYO Pharma Limited - Ordinary Shares was at 10/01/26 02:12 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.